It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
In your 30s? It's time to boost your income! Discover practical strategies to increase your earnings and achieve your goals.
19,736 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A new Goldman Sachs retirement survey projects retirement costs could climb to about $2.57 million by 2043, underscor...
DVY’s 3.3% yield looks weak when set against a 4.55% 10-year Treasury, underscoring a shifting landscape for income-f...
A bond ETF that regularly resets its income for inflation offers a unique hedge in today’s rate environment. Retirees...
As market yields shift, a growing cohort of investors turning $400,000 into passive income is using Delaware Statutor...
Schd’s $71.6 billion portfolio has posted a 20% year-to-date price gain alongside a 3.3% yield, underscoring the appe...
A 53-year-old investor says i’m with $1.5 million and dreams of Carmel and a sports car. The reality check shows high...
The CFPB signals that immigration status could influence a borrower's ability to repay a loan, potentially reshaping ...
PBDC, a focused BDC ETF, slashed its April 2026 payout by about 14% to $0.71273 per share. With shares near $27 and a...
As market nerves remain tied to crude prices, the VanEck Energy Income ETF (EINC) continues to offer a solid 3.2%-3.6...
Investors are weighing whether EWO’s latest payouts can be sustained. This dividend safety check: austrian analyzes b...
As volatility rattles markets in early 2026, retirees are turning to a trio of low-volatility ETFs that blend income ...